Cargando…
In Silico Structure-Based Repositioning of Approved Drugs for Spike Glycoprotein S2 Domain Fusion Peptide of SARS-CoV-2: Rationale from Molecular Dynamics and Binding Free Energy Calculations
The membrane-anchored spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a pivotal role in directing the fusion of the virus particle mediated by the host cell receptor angiotensin-converting enzyme 2 (ACE-2). The fusion peptide region of the S protein S2 domain pr...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511214/ https://www.ncbi.nlm.nih.gov/pubmed/32963099 http://dx.doi.org/10.1128/mSystems.00382-20 |
_version_ | 1783585919201181696 |
---|---|
author | Shekhar, Nishant Sarma, Phulen Prajapat, Manisha Avti, Pramod Kaur, Hardeep Raja, Anupam Singh, Harvinder Bhattacharya, Anusuya Sharma, Saurabh Kumar, Subodh Prakash, Ajay Medhi, Bikash |
author_facet | Shekhar, Nishant Sarma, Phulen Prajapat, Manisha Avti, Pramod Kaur, Hardeep Raja, Anupam Singh, Harvinder Bhattacharya, Anusuya Sharma, Saurabh Kumar, Subodh Prakash, Ajay Medhi, Bikash |
author_sort | Shekhar, Nishant |
collection | PubMed |
description | The membrane-anchored spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a pivotal role in directing the fusion of the virus particle mediated by the host cell receptor angiotensin-converting enzyme 2 (ACE-2). The fusion peptide region of the S protein S2 domain provides SARS-CoV-2 with the biological machinery needed for direct fusion to the host lipid membrane. In our present study, computer-aided drug design strategies were used for the identification of FDA-approved small molecules using the optimal structure of the S2 domain, which exhibits optimal interaction ratios, structural features, and energy variables, which were evaluated based on their performances in molecular docking, molecular dynamics simulations, molecular mechanics/generalized Born model and solvent accessibility binding free energy calculations of molecular dynamics trajectories, and statistical inferences. Among the 2,625 FDA-approved small molecules, chloramphenicol succinate, imipenem, and imidurea turned out to be the molecules that bound the best at the fusion peptide hydrophobic pocket. The principal interactions of the selected molecules suggest that the potential binding site at the fusion peptide region is centralized amid the Lys790, Thr791, Lys795, Asp808, and Gln872 residues. IMPORTANCE The present study provides the structural identification of the viable binding residues of the SARS-CoV-2 S2 fusion peptide region, which holds prime importance in the virus’s host cell fusion and entry mechanism. The classical molecular mechanics simulations were set on values that mimic physiological standards for a good approximation of the dynamic behavior of selected drugs in biological systems. The drug molecules screened and analyzed here have relevant antiviral properties, which are reported here and which might hint toward their utilization in the coronavirus disease 2019 (COVID-19) pandemic owing to their attributes of binding to the fusion protein binding region shown in this study. |
format | Online Article Text |
id | pubmed-7511214 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-75112142020-10-01 In Silico Structure-Based Repositioning of Approved Drugs for Spike Glycoprotein S2 Domain Fusion Peptide of SARS-CoV-2: Rationale from Molecular Dynamics and Binding Free Energy Calculations Shekhar, Nishant Sarma, Phulen Prajapat, Manisha Avti, Pramod Kaur, Hardeep Raja, Anupam Singh, Harvinder Bhattacharya, Anusuya Sharma, Saurabh Kumar, Subodh Prakash, Ajay Medhi, Bikash mSystems Research Article The membrane-anchored spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a pivotal role in directing the fusion of the virus particle mediated by the host cell receptor angiotensin-converting enzyme 2 (ACE-2). The fusion peptide region of the S protein S2 domain provides SARS-CoV-2 with the biological machinery needed for direct fusion to the host lipid membrane. In our present study, computer-aided drug design strategies were used for the identification of FDA-approved small molecules using the optimal structure of the S2 domain, which exhibits optimal interaction ratios, structural features, and energy variables, which were evaluated based on their performances in molecular docking, molecular dynamics simulations, molecular mechanics/generalized Born model and solvent accessibility binding free energy calculations of molecular dynamics trajectories, and statistical inferences. Among the 2,625 FDA-approved small molecules, chloramphenicol succinate, imipenem, and imidurea turned out to be the molecules that bound the best at the fusion peptide hydrophobic pocket. The principal interactions of the selected molecules suggest that the potential binding site at the fusion peptide region is centralized amid the Lys790, Thr791, Lys795, Asp808, and Gln872 residues. IMPORTANCE The present study provides the structural identification of the viable binding residues of the SARS-CoV-2 S2 fusion peptide region, which holds prime importance in the virus’s host cell fusion and entry mechanism. The classical molecular mechanics simulations were set on values that mimic physiological standards for a good approximation of the dynamic behavior of selected drugs in biological systems. The drug molecules screened and analyzed here have relevant antiviral properties, which are reported here and which might hint toward their utilization in the coronavirus disease 2019 (COVID-19) pandemic owing to their attributes of binding to the fusion protein binding region shown in this study. American Society for Microbiology 2020-09-22 /pmc/articles/PMC7511214/ /pubmed/32963099 http://dx.doi.org/10.1128/mSystems.00382-20 Text en Copyright © 2020 Shekhar et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Shekhar, Nishant Sarma, Phulen Prajapat, Manisha Avti, Pramod Kaur, Hardeep Raja, Anupam Singh, Harvinder Bhattacharya, Anusuya Sharma, Saurabh Kumar, Subodh Prakash, Ajay Medhi, Bikash In Silico Structure-Based Repositioning of Approved Drugs for Spike Glycoprotein S2 Domain Fusion Peptide of SARS-CoV-2: Rationale from Molecular Dynamics and Binding Free Energy Calculations |
title | In Silico Structure-Based Repositioning of Approved Drugs for Spike Glycoprotein S2 Domain Fusion Peptide of SARS-CoV-2: Rationale from Molecular Dynamics and Binding Free Energy Calculations |
title_full | In Silico Structure-Based Repositioning of Approved Drugs for Spike Glycoprotein S2 Domain Fusion Peptide of SARS-CoV-2: Rationale from Molecular Dynamics and Binding Free Energy Calculations |
title_fullStr | In Silico Structure-Based Repositioning of Approved Drugs for Spike Glycoprotein S2 Domain Fusion Peptide of SARS-CoV-2: Rationale from Molecular Dynamics and Binding Free Energy Calculations |
title_full_unstemmed | In Silico Structure-Based Repositioning of Approved Drugs for Spike Glycoprotein S2 Domain Fusion Peptide of SARS-CoV-2: Rationale from Molecular Dynamics and Binding Free Energy Calculations |
title_short | In Silico Structure-Based Repositioning of Approved Drugs for Spike Glycoprotein S2 Domain Fusion Peptide of SARS-CoV-2: Rationale from Molecular Dynamics and Binding Free Energy Calculations |
title_sort | in silico structure-based repositioning of approved drugs for spike glycoprotein s2 domain fusion peptide of sars-cov-2: rationale from molecular dynamics and binding free energy calculations |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511214/ https://www.ncbi.nlm.nih.gov/pubmed/32963099 http://dx.doi.org/10.1128/mSystems.00382-20 |
work_keys_str_mv | AT shekharnishant insilicostructurebasedrepositioningofapproveddrugsforspikeglycoproteins2domainfusionpeptideofsarscov2rationalefrommoleculardynamicsandbindingfreeenergycalculations AT sarmaphulen insilicostructurebasedrepositioningofapproveddrugsforspikeglycoproteins2domainfusionpeptideofsarscov2rationalefrommoleculardynamicsandbindingfreeenergycalculations AT prajapatmanisha insilicostructurebasedrepositioningofapproveddrugsforspikeglycoproteins2domainfusionpeptideofsarscov2rationalefrommoleculardynamicsandbindingfreeenergycalculations AT avtipramod insilicostructurebasedrepositioningofapproveddrugsforspikeglycoproteins2domainfusionpeptideofsarscov2rationalefrommoleculardynamicsandbindingfreeenergycalculations AT kaurhardeep insilicostructurebasedrepositioningofapproveddrugsforspikeglycoproteins2domainfusionpeptideofsarscov2rationalefrommoleculardynamicsandbindingfreeenergycalculations AT rajaanupam insilicostructurebasedrepositioningofapproveddrugsforspikeglycoproteins2domainfusionpeptideofsarscov2rationalefrommoleculardynamicsandbindingfreeenergycalculations AT singhharvinder insilicostructurebasedrepositioningofapproveddrugsforspikeglycoproteins2domainfusionpeptideofsarscov2rationalefrommoleculardynamicsandbindingfreeenergycalculations AT bhattacharyaanusuya insilicostructurebasedrepositioningofapproveddrugsforspikeglycoproteins2domainfusionpeptideofsarscov2rationalefrommoleculardynamicsandbindingfreeenergycalculations AT sharmasaurabh insilicostructurebasedrepositioningofapproveddrugsforspikeglycoproteins2domainfusionpeptideofsarscov2rationalefrommoleculardynamicsandbindingfreeenergycalculations AT kumarsubodh insilicostructurebasedrepositioningofapproveddrugsforspikeglycoproteins2domainfusionpeptideofsarscov2rationalefrommoleculardynamicsandbindingfreeenergycalculations AT prakashajay insilicostructurebasedrepositioningofapproveddrugsforspikeglycoproteins2domainfusionpeptideofsarscov2rationalefrommoleculardynamicsandbindingfreeenergycalculations AT medhibikash insilicostructurebasedrepositioningofapproveddrugsforspikeglycoproteins2domainfusionpeptideofsarscov2rationalefrommoleculardynamicsandbindingfreeenergycalculations |